Disclosure of GSK payments to HCPs and HCOs in France in 2016

Our path towards transparency

GSK supports the Code wholeheartedly, because it is the right thing to do and is consistent with our values of integrity, transparency, patient first and respect. We believe that the Code is consistent with a global trend towards greater transparency and accountability, driven by the expectations of healthcare communities and society worldwide. It is with this mindset that we will implement the EFPIA Disclosure Code while respecting the French legal requirement (French Sunshine act).

We have been pioneers in...

Over the past decade we have challenged the traditional industry model by being first to increase transparency around clinical trial data; being first to declare support to patient organisations; and being first to abolish individual sales targets for medical representatives.

NECESSARY COLLABORATIONS

Collaboration with health professionals and organisations are fundamental to reach a common objective: the advancement of medical research in benefit of the patients.

WHAT ARE TRANSFERS OF VALUE?

They are the collaborations and contributions, both monetary and non-monetary, made to health professionals and organisations.

WHAT ARE THESE COLLABORATIONS USED FOR?

- Donations and collaborations with health organisations
- Training activities and scientific / professional meetings
- R&D activities
- Provision of services (consultancy, speeches)

WHAT DOES INDIVIDUALISED DISCLOSURE MEAN?

We have undertaken for Europe to publish data individually and therefore, have requested consent for dissemination to all healthcare professionals that would like to work with us, following the maxim “No dissemination consent, no contract”. In consideration of previously existing French Sunshine Act (2011), the EFPIA Board endorsed deviations from the EFPIA Disclosure Code in France.

The figures

Laboratoire GlaxoSmithKline AND ViiV Healthcare SAS has collaborated with 375 HCPs and 248 health organisations in France in 2016.

Total: 11 521 198 €

R&D
- Aggregate: 7 122 225 €

HCO
- Aggregate: 4 011 089 €

HCP
- Aggregate: 387 884 €

FRENCH SUNSHINE ACT

The publication of transfers of value by GSK in France pertaining to the EFPIA code will consist in aggregate and anonymous information for the activities Laboratoire GlaxoSmithKline and ViiV Healthcare SAS.

With regards to the ongoing last evolution of the French legislation, Laboratoire GlaxoSmithKline and ViiV Healthcare SAS and GSK Santé Grand Public will publish in October 2017 all the individual data required by the new legislation, from 2015 at least which will go even further than the EFPIA disclosure code.

Contact:

EFPIA Disclosure-France

Date of preparation: 21 / 06 / 2017